EOSYNQ Trademark

Trademark Overview

On Thursday, July 8, 2021, a trademark application was filed for EOSYNQ with the United States Patent and Trademark Office. The USPTO has given the EOSYNQ trademark a serial number of 90817355. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Tuesday, July 2, 2024. This trademark is owned by TEVA Pharmaceutical Industries Limited. The EOSYNQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of inflammatory disorders
eosynq

General Information

Serial Number90817355
Word MarkEOSYNQ
Filing DateThursday, July 8, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateTuesday, July 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 15, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of inflammatory disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 15, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTEVA Pharmaceutical Industries Limited
Party Type20 - Owner at Publication
Legal Entity Type13 - Limited Partnership
AddressTel Aviv 6944020
IL
Party NameTEVA Pharmaceutical Industries Limited
Party Type10 - Original Applicant
Legal Entity Type13 - Limited Partnership
AddressTel Aviv 6944020
IL

Trademark Events

Event DateEvent Description
Tuesday, March 15, 2022ASSIGNED TO EXAMINER
Monday, July 12, 2021NEW APPLICATION ENTERED
Wednesday, September 15, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 16, 2022NON-FINAL ACTION E-MAILED
Wednesday, March 16, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, March 17, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, March 16, 2022NON-FINAL ACTION WRITTEN
Thursday, March 17, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, March 17, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sunday, October 9, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, November 15, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 15, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, October 26, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 10, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, August 14, 2023ABANDONMENT - NO USE STATEMENT FILED
Monday, July 10, 2023SOU EXTENSION 1 FILED
Tuesday, August 15, 2023PETITION TO REVIVE-GRANTED
Tuesday, August 15, 2023SOU EXTENSION RECEIVED WITH TEAS PETITION
Tuesday, August 15, 2023TEAS PETITION TO REVIVE RECEIVED
Thursday, January 4, 2024SOU EXTENSION 2 FILED
Monday, August 14, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, August 15, 2023NOTICE OF REVIVAL - E-MAILED
Monday, September 18, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, September 19, 2023SOU EXTENSION 1 GRANTED
Wednesday, September 20, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 4, 2024SOU TEAS EXTENSION RECEIVED
Thursday, January 4, 2024SOU EXTENSION 2 GRANTED
Saturday, January 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 2, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, July 2, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 2, 2024SOU EXTENSION 3 GRANTED
Tuesday, July 2, 2024SOU EXTENSION 3 FILED

Related Keywords

eosynq disorders inflammatory treatment preparations pharmaceutical